Page 41 Volume 20 - N1 - 2012

Dor (2012) 20
Bibliografia capsaicin patch, on epidermal nerve fiber density and sensory func-
tion in healthy volunteers. J Pain. 2010;11(6):579-87.
1. Schmader KE. Epidemiology and impact on quality of life of pos- 14. Nolano M, Simone DA, Wendelschafer-Crabb G, Johnson T, Hazen
therpetic neuralgia and painful diabetic neuropathy. Clin J Pain. E, Kennedy WR. Topical capsaicin in humans: Parallel loss of epi-
2002;18(6):350-4. dermal nerve fibers and pain sensation. Pain. 1999;81(1-2):135-45.
2. Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: Re- 15. Data on file. Physical, chemical and pharmaceutical properties and
definition and a grading system for clinical and research purposes. formulation: NGX-4010 (part 1). 2009. Astellas Pharma Europe Ltd,
Neurology. 2008;70(18):1630-5. Staines, Middlesex, UK.
3. Gilron I, Watson PN, Cahill CM, Moulin DE. Neuropathic pain: a 16. Irving GA, Backonja MM, Dunteman E, et al.; NGX-4010 C117 Study © Permanyer Portugal 2012
practical guide for the clinician. CMAJ. 2006;175(3):265-75. Group. A multicenter, randomized, double-blind, controlled study of
4. Neuropathic Pain Website [Internet]. Neuropathic pain network. NGX-4010, a high-concentration capsaicin patch for the treatment
2009. Disponível em: www.neuropathicpainnetwork.org/english/ of postherpetic neuralgia. Pain Med. 2011;12(1):99-109.
index.asp 17. Backonja M, et al. NGX-4010, a high-concentration capsaicin patch
5. O’Connor AB, Dworkin RH. Treatment of neuropathic pain: An over- for the treatment of postherpetic neuralgia: a randomised, double-
view of recent guidelines. Am J Med. 2009;122(10 Suppl):S22-32. blind study. Lancet Neurol. 2008; 7(12):1106-12.
6. Woolf CJ, Mannion RJ. Neuropathic pain. Aetiology, symptoms, 18. Backonja M, Malan TP, Vanhove GF, Tobias JK; C102/106 Study
mechanisms, and management. Lancet. 1999;353(9168):1959-64. Group. NGX-4010, a high-concentration capsaicin patch for the
7. Jensen TS, Madsen CS, Finnerup NB. Pharmacology and treatment treatment of postherpetic neuralgia: a randomised, double-blind
of neuropathic pain. Curr Opin Neurol. 2009;22(5):467-74. study with an open-label extension. Pain Med. 2010;11(4):600-8.
8. Noto C, Pappagallo M, Szallasi A. NGX-4010, a high-concentration 19. Webster LR, Malan TP, Tuchman MM, Mollen MD, Tobias JK, Vanhove
capsaicin dermal patch for lasting relief of peripheral neuropathic GF. A multicenter, randomized, double-blind, controlled dose finding
pain. Curr Opin Investig Drugs. 2009;10(7):702-10. study of NGX-4010, a high-concentration capsaicin patch for the
9. Knotkova H, Pappagallo M, Szallasi A. Capsaicin (TRPV1 agonist) treatment of postherpetic neuralgia. J Pain. 2010;11(10):972-82.
therapy for pain relief: farewell or revival? Clin J Pain. 2008;24(2):152-4. 20. Webster LR, Tark M, Rauck R, Tobias JK, Vanhove GF. Effect of
10. Caterina MJ, Julius D. The vaniloid receptor: A molecular gateway duration of postherpetic neuralgia on efficacy analyses in a multi-
to the pain pathway. Annu Rev Neurosci. 2001;24:487-517. centre, randomized, controlled study of NGX-4010, an 8% capsaicin
11. Premkumar LS, Sikand P. TRPV1: A target for next generation anal- patch evaluated for the treatment of postherpetic neuralgia. BMC
gesics. Curr Neuropharmacol. 2008;6(2):159-212. Neurol. 2010;11(10):92.
12. Szallasi A, Blumberg PM. Vaniloid receptors and mechanisms. Phar- 21. European Medicines Agency. Qutenza (capsaicin) 179 mg cutane-
macol Ver. 1999;51(2):159-212. ous patch: summary of product characteristics. Disponível em: www.
13. Kennedy WR, Vanhove GF, Lu SP, et al. A randomized, controlled, open- ema.europa.eu/humandocs/PDFs/EPAR/qutenza/emea-combined-
label studt of the long-term effects of NGX-4010, a high concentration h909en.pdf Sem o consentimento prévio por escrito do editor, não se pode reproduzir nem fotocopiar nenhuma parte desta publicação.

DOR

40